Dr Helen Bright FRSM, Chief Scientific Officer, Centauri Therapeutics discusses the intricacies of the body’s natural immune defences and explores how cutting-edge research is seeking to exploit it in order to drive development of a broad spectrum of innovative new immunotherapeutic technologies. The body's natural immune defences, whether in response… Read More
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More
iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC). Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC… Read More
Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress. The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201. The study is a European multicentre and… Read More
Oncimmune Holdings has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a cancer research organisation and its cancer hospitals have more than 1,100 therapeutic and non-therapeutic clinical trials in progress. Under this agreement, Oncimmune… Read More
Evaluation of checkpoint inhibitor therapies using an MLR assay, is an exclusive webinar that will be hosted by DDW and supported by Sartorius. It will provide valuable information for immuno-oncology research and the cancer immunotherapy drug discovery process. The event is now available to watch on demand here Sartorius recognises… Read More
